Project Description

Dr. Claudia Böhm

Certified Specialist for Intellectual Property Law
Lecturer for competition law at the University of Münster
Partner in our Munich office

Widenmayerstraße 6
80538 München

T +49 / 89 / 22 33 11
F +49 / 89 / 21 21 59 59

cboehm@boetticher.com

Download vcf-card

Best Lawyers Award Badge

Practice Areas

  • Pharmaceutical law
  • Competition law
  • Real estate law
Expertise

Claudia Böhm has 30 years of expertise in pharmaceutical law, in particular as regards the sale, promotion and parallel imports of drugs and medical products. Claudia Böhm in particular specializes in litigation regarding the sale and promotion of drugs, especially in the expeditious enforcement of claims in proceedings for temporary restraining orders, dealing with the multi-disciplinary challenge of processing the relevant medical and scientific data in a litigation environment. Her clients in these areas include well-known national and international corporate players in the pharmaceutical industry. She also provides consulting services for entrepreneurs and companies from other industries in all matters pertaining to unfair competition, in particular with respect to advertising focused on environmental issues and technological standards. Claudia Böhm represents the legal interests of her clients both in and out of court.
Qualifications

  • Legal studies at the University of Münster, Germany
  • Scientific assistant from 1989 to 1992 at the Institute for Roman Law Institute at the University of Münster
  • Admitted to the German bar in 1993
  • Certified Specialist for Intellectual Property Law
Recognitions

  • Claudia Böhm will be one of “Germany’s best lawyers” in the field of pharmaceutical law, advertisement law and litigation in 2022 according to Handelsblatt/Best Lawyers
  • JUVE Handbook 2019/2020: Healthcare, Pharmaceutical & Medical Product Law: „Often Recommended: Dr. Claudia Böhm (,Very good service and availability high quality of advice’; ‘I have rarely experienced that a cooperation works so well’; client)“
  • JUVE Handbook 2019/2020: Healthcare, Pharmaceutical & Medical Product Law: „Often Recommended: Dr. Claudia Böhm (HWG processes)“
  • JUVE Handbook 2017/2018: Healthcare, Pharmaceutical & Medical Product Law: „Frequently Recommended: Dr. Claudia Böhm (,combative and professional top’; competitor)“
  • JUVE Handbook 2016/2017: Healthcare: „Frequently Recommended: Dr. Claudia Böhm“
  • JUVE Handbook 2015/2016: Healthcare: „Frequently Recommended: Dr. Claudia Böhm (,expertise in the field of vaccines’; client)“
  • JUVE Handbook 2014/2015: Healthcare: „Frequently Recommended: Dr. Claudia Böhm (,good HWG lawyer’; competitor)“
  • German law publication Legal 500 Deutschland 2011/2012: „… known for her expertise in pharmaceutical law“
Affiliations

  • Member of the German Association for the Protection of Intellectual Property Rights (GRUR)
Publications

Claudia Böhm has (co-)authored numerous articles and regularly publishes articles in various law magazines on subject matters such as:

  • Comment on BGH decision of 02.06.2022 (I ZR 93/21) “Zur Irreführung der Bewerbung einer Kindermilch mit der Aussage ‘7 x mehr Vitamin D’ – Verbindung mehrerer Verletzungsformen mit ‘und/oder’-Unterlassungsantrag”, in German law publication Der IP-Rechtsberater (IPRB) 2022, 220 ff.;
  • Article “Cannbidiol(CBD-products): Pharmaceuticals, Food, Novel Food or Cosmetics?Legal classification and assessment of CBD products”, in Arzneimittel & Recht (A&R) 2020, 210 ff.
  • Article “Health related advertisement with information from the summary of product characteristics – On the significance of the content of the marketing authorisation of a medicinal product for the scientific substantiation of technical information in health related advertisement” (“Gesundheitswerbung mit Angaben aus der Fachinformation – Zur Bedeutung des Inhalts der Zulassung eines Arzneimittels für die wissenschaftliche Absicherung fachlicher Angaben in der Gesundheitswerbung”) in German law publication Der IP-Rechtsberater (IPRB) 2019, 181 ff.;
Publications, Cont'd
  • Comment on Higher Regional Court of Hamburg decision (3 U 32/17) of Aug 3, 2017 on Advertising with data of the SPC (“Zulassungsbegründende post-hoc-Analyse”), in German law publication Der IP-Rechts-Berater (IPRB) 2017, 273
  • Comment on Higher Regional Court of Cologne decision (6 U 65/16) of Jan 20, 2017 on Advertising with data of the SPC (“Äquipotenzbehauptung”), in German law publication Der IP-Rechts-Berater (IPRB) 2017, 102;
  • Comment on German Federal Court of Justice (BGH) decision (I ZR 221/15) from Dec 15, 2016 on the determination of the motion for cease and desist („Bestimmtheit des Unterlassungsantrages“) in German law publication Der IP-Rechts-Berater (IPRB) 2017, 54;
  • Comment on Higher Regional Court of Düsseldorf decision (I-15 U 119/14) of Sept 3, 2015 on penalty contracts and extent of cease and desist declarations (Zustandekommen eines Vertragsstrafevertrages und Umfang der Unterlassungsverpflichtung), in German law publication Der IP-Rechts-Berater (IPRB), 2016, 56;
  • Comment on Higher Regional Court of Hamburg decision (3 U 193/13) of Sept 24, 2014 on gratis distribution of pharmaceuticals to pharmacists (Kostenlose Abgabe von Arzneimitteln an Apotheker ‘zu Demonstrationszwecken’, in German law publication Der IP-Rechts-Berater (IPRB), 2015, 131;
  • Article on current legislative tendencies in medical advertising law (“Aktuelle Tendenzen in der Rechtsprechung zur Arzneimittelwerbung”), Part 1, in German law publication Der IP-Rechts-Berater (IPRB), 2013, 250;
  • Comment on German Federal Court of Justice (BGH) decision (I ZR 62/11) from Feb 6, 2013 regarding misleading advertising for medical drugs based on scientific studies (“Irreführung durch auf Studien gestützte Werbung für Arzneimittel”) in German law publication Der IP-Rechts-Berater (IPRB), 2013, 151
  • Article on the physician’s liability for deficient pharmaceutical treatments (“Die Haftung des Arztes für fehlerhafte Arzneimitteltherapien”), PaPfleReQ, 2013, 45.
Languages

German, English